– USA, CA – InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Ann Merrifield to its Board of Directors. Ms. Merrifield most recently was President and Chief Executive Officer at PathoGenetix, a genomics company that developed and commercialized an automated system for rapid bacterial identification from complex samples.
Before joining PathoGenetix in 2012, Ms. Merrifield spent 18 years at the Genzyme Corporation, serving in a number of leadership roles. In her most recent position, she was selected by the CEO to serve as Senior Vice President, Business Excellence for two years before the Sanofi acquisition. Prior to that, she served as President of Genzyme Biosurgery, where she led a turnaround from an over $75M loss in 2002 to a profit of more than $200M in 2009. She served as President of Genzyme Genetics before her position at Genzyme Biosurgery, where she shaped the company’s genetic diagnostics business through product and service differentiation and strategic acquisitions.
Ms. Merrifield came to Genzyme from Bain and Company, where she was a partner, and Aetna Life & Casualty, where her role was as an investment officer. She earned a Bachelor of Arts in Zoology and a Master of Education from The University of Maine, and a Master of Business Administration from the Amos Tuck School of Business at Dartmouth College.
Mark Perrin, InVivo’s CEO, said, “We are delighted to have Ann join the Board of Directors. She has amassed an invaluable amount of experience and expertise over her long career in industry. Besides playing a key role in Genzyme’s rise to prominence, she serves as Trustee and Director a number of boards, including Flexim Therapeutics, Partners Continuing Care and the YMCA of Greater Boston.”
John McCarthy, InVivo’s Chairman of the Board, added, “We are committed to bringing seasoned industry professionals to join the Board of Directors and couldn’t be happier with Ann’s appointment. We believe her leadership experience will be instrumental as we look to new and exciting opportunities.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, MA.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
